Table 3.

Characteristics of included studies with LVMI as outcome

Author, Year (Reference)Study Duration, MonthsNumber of Patients (medication)Mean Duration on HD, Months (SD)Mean Baseline LVMI, g/m2 (SD)Mean Baseline SBP, mmHg (SD)Mean Baseline LVEF, % (SD)
TxCTxCTxCTxCTxC
London, 1994 (32)1214 (perindopril)10 (nitrendipine)86 (67)90 (85)188 (37)182 (47)177 (29)177 (17)NRNR
Shibasaki, 2002 (26)610 (losartan)10 (amlodipine)NRNR154.5 (31)156.6 (23)NRNR71 (7)70 (11)
Shibasaki, 2002 (26)610 (enalapril)10 (amlodipine)NRNR155.6 (45)156.6 (23)NRNR69 (8)70 (11)
Kanno, 2004 (33)1212 (losartan)12 (placebo)NRNR145 (17)147 (10)153 (14)156 (11)52 (6)50 (6)
Matsumoto, 2006 (30)612 (imidapril)15 (placebo)84 (83)108 (93)132 (35)129 (23)152 (17)148 (16)NRNR
Yu, 2006 (31)1224 (ramipril)22 (placebo)80 (59)77 (53)112 (26)105 (21)125 (26)120 (26)73 (9)71 (7)
  • LVEF, LV ejection fraction.